183 related articles for article (PubMed ID: 24002095)
1. Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro.
Moss DM; Liptrott NJ; Curley P; Siccardi M; Back DJ; Owen A
Antimicrob Agents Chemother; 2013 Nov; 57(11):5612-8. PubMed ID: 24002095
[TBL] [Abstract][Full Text] [Related]
2. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir.
Moss DM; Kwan WS; Liptrott NJ; Smith DL; Siccardi M; Khoo SH; Back DJ; Owen A
Antimicrob Agents Chemother; 2011 Feb; 55(2):879-87. PubMed ID: 21078936
[TBL] [Abstract][Full Text] [Related]
3. MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.
Reznicek J; Ceckova M; Ptackova Z; Martinec O; Tupova L; Cerveny L; Staud F
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696229
[TBL] [Abstract][Full Text] [Related]
4.
Anderson LL; Etchart MG; MacNair L; Land MH; Mosesova IA; Bonn-Miller MO; Arnold JC
Cannabis Cannabinoid Res; 2022 Jun; 7(3):304-317. PubMed ID: 33998860
[No Abstract] [Full Text] [Related]
5. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
Minematsu T; Iwai M; Umehara K; Usui T; Kamimura H
Drug Metab Dispos; 2010 Jan; 38(1):1-4. PubMed ID: 19833842
[TBL] [Abstract][Full Text] [Related]
6. Interaction potential of etravirine with drug transporters assessed in vitro.
Zembruski NC; Haefeli WE; Weiss J
Antimicrob Agents Chemother; 2011 Mar; 55(3):1282-4. PubMed ID: 21189339
[TBL] [Abstract][Full Text] [Related]
7. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3).
Bourdet DL; Pritchard JB; Thakker DR
J Pharmacol Exp Ther; 2005 Dec; 315(3):1288-97. PubMed ID: 16141367
[TBL] [Abstract][Full Text] [Related]
8. MPP
Mocking TAM; Sijben HJ; Vermeulen YW; IJzerman AP; Heitman LH
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163125
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
10. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
Patel A; Tiwari AK; Chufan EE; Sodani K; Anreddy N; Singh S; Ambudkar SV; Stephani R; Chen ZS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):189-99. PubMed ID: 23673445
[TBL] [Abstract][Full Text] [Related]
11. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1).
Nies AT; Herrmann E; Brom M; Keppler D
Naunyn Schmiedebergs Arch Pharmacol; 2008 Feb; 376(6):449-61. PubMed ID: 18157518
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).
Nies AT; Hofmann U; Resch C; Schaeffeler E; Rius M; Schwab M
PLoS One; 2011; 6(7):e22163. PubMed ID: 21779389
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein.
Knop J; Misaka S; Singer K; Hoier E; Müller F; Glaeser H; König J; Fromm MF
PLoS One; 2015; 10(10):e0139370. PubMed ID: 26426900
[TBL] [Abstract][Full Text] [Related]
14. Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1.
Gromicho M; Dinis J; Magalhães M; Fernandes AR; Tavares P; Laires A; Rueff J; Rodrigues AS
Leuk Lymphoma; 2011 Oct; 52(10):1980-90. PubMed ID: 21663515
[TBL] [Abstract][Full Text] [Related]
15. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.
Giannoudis A; Davies A; Lucas CM; Harris RJ; Pirmohamed M; Clark RE
Blood; 2008 Oct; 112(8):3348-54. PubMed ID: 18669873
[TBL] [Abstract][Full Text] [Related]
16. Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.
Martinec O; Huliciak M; Staud F; Cecka F; Vokral I; Cerveny L
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481446
[TBL] [Abstract][Full Text] [Related]
17. ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein.
Dickens D; Owen A; Alfirevic A; Pirmohamed M
Pharmacogenet Genomics; 2013 Jun; 23(6):314-23. PubMed ID: 23619510
[TBL] [Abstract][Full Text] [Related]
18. Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials.
Mulgaonkar A; Venitz J; Gründemann D; Sweet DH
Antimicrob Agents Chemother; 2013 Jun; 57(6):2705-11. PubMed ID: 23545524
[TBL] [Abstract][Full Text] [Related]
19. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
[TBL] [Abstract][Full Text] [Related]
20. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
